Background: Breast cancer subtype is a key determinant in treatment decision-making, and also effects survival outcome. In this population-based study, in-depth analyses were performed to examine the impact that breast cancer subtype and receipt of guidelineconcordant adjuvant systemic therapy (AST) have on survival using a population-based cancer registry's data. Methods: Women aged $20 years with microscopically confirmed stage I-III breast cancer diagnosed in 2011 were identified from the Louisiana Tumor Registry. Breast cancer subtypes were categorized based on hormone receptor (HR) and HER2 status. Guideline-concordant treatment was defined using the NCCN Guidelines for Breast Cancer. Logistic regression was applied to identify factors associated with guidelineconcordant AST receipt. Kaplan-Meier survival curves were generated to compare survival among subtypes by AST receipt status, and a semiparametric additive hazard model was used to verify the factors impacting survival outcome. Results: Of 2,214 eligible patients, most (70.8%) were HR1/HER2-followed by HR-/HER2-(14.4%), and 78.6% received guideline-concordant AST. Compared with patients with the HR1/HER21 subtype, women with other subtypes were more likely to be guideline-concordant after adjusting for sociodemographic and clinical variables. Women with the HR-/HER21 or HR-/HER2-subtype had a higher risk of any-cause and breast cancer-specific death than those with the HR1/HER21 subtype. Those who did not receive AST had an additional adjusted hazard of 0.0191 (P5.0001) in overall survival and 0.0126 (P5.0011) in cause-specific survival compared with those who received AST. Conclusions: Most patients received guideline-concordant AST, except for those with the HR1/HER21 subtype. Patients receiving guideline-adherent adjuvant therapy had better survival outcomes across all breast cancer subtypes.
Background
Since the molecular phenotypes of breast carcinomas were distinguished by gene expression patterns in 2000, breast cancer is no longer considered a single disease but rather a group of molecularly distinct neoplastic disorders. [1] [2] [3] [4] Based on hormone receptor (HR) status, including estrogen receptor (ER) and progesterone receptor (PR), HER2 status, and proliferation markers or histologic grade, 4 distinct intrinsic molecular subtypes of breast cancer have been identified: luminal A, luminal B, basal-like (triple-negative: ER-/PR-/HER2-), and HER21/ER-. 1, 4 These subtypes vary by race and influence survival rate. 5 When physicians prescribe appropriate adjuvant systemic therapies (ASTs) for patients with breast cancer, molecular subtypes are a key determinant. Clinical trials have demonstrated that patients with HR1 (ER1 and/or PR1) breast cancer benefit from tamoxifen, those with HR-(ER-and PR-) benefit from adjuvant chemotherapy, and those with HER21 disease benefit from trastuzumab by decreasing recurrence and increasing survival. [6] [7] [8] [9] The significance of these tumor markers led ASCO in 2007 to recommend measuring ER/PR and HER2 expression and/or amplification in every primary invasive breast cancer. 10 In addition, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer have taken ER/PR and HER2 status into account in guiding clinical care. 11 Few population-based studies have examined the association of breast cancer subtypes with guidelineconcordant AST and survival. Studies on guidelineconcordant AST have mainly focused on adjuvant hormone therapy and chemotherapy, which was based on HR (ER and PR) status, 12, 13 or examined the use of trastuzumab only. 14 No studies have examined AST with hormone therapy, chemotherapy, and trastuzumab together by breast cancer subtype. The goal of the present study was to investigate whether receipt of guideline-concordant AST varied by breast cancer subtype after adjusting for patients' sociodemographic and tumor characteristics, and to examine the impact of guideline-concordant treatment status and cancer subtype on survival outcome.
Methods

Data Source and Study Cohort
Data on female breast cancer were obtained from the Louisiana Tumor Registry (LTR), a population-based specialized cancer registry funded by the Centers for Disease Control and Prevention's (CDC's) National Program of Cancer Registries that participates in the CDC-funded project Enhancing Cancer Registry Data for Comparative Effectiveness Research (CER) and the SEER registry. The CDC-CER registries reabstracted medical records and collected detailed and complete first-course treatment information, including type of surgery, radiation, and all systemic treatments, from all sources for patients diagnosed with breast cancer in 2011. 15 Because gene expression profiling is not performed routinely in many healthcare facilities or collected by populationbased cancer registries, ER, PR, and HER2 status based on immunohistochemistry and/or fluorescence in situ hybridization (FISH) results are commonly used as surrogates to categorize breast cancer into 4 subtypes: HR1/ HER21, HR1/HER2-, HR-/HER21, and HR-/HER2-. 16 Eligible patients were women with breast cancer aged $20 years with microscopically confirmed stage I-III disease diagnosed in 2011 and who had undergone total mastectomy or breast-conserving surgery plus radiation. Eligibility was restricted to patients with histologic codes 8050, 8140, 8201, 8211, 8401, 8480, 8481, and 8500-8575 and with breast cancer as the only, first, or second primary cancer. Women who died within 30 days after surgery were excluded. A total of 32 patients were diagnosed with either bilateral breast cancers or 2 ipsilateral primary tumors in 2011; only the first primary was included. Selection of eligible patients is detailed in Figure 1 .
Definition of Guideline-Concordant AST
Systemic therapies included in this study were hormonal, chemotherapy, and trastuzumab. Receipt of guidelineconcordant AST was defined as treatment based on the NCCN Guidelines for Breast Cancer, 11 which takes into account cancer stage, histology, and subtype; tumor size; lymph node status; and risk score of recurrence (Table 1) for pathologically staged breast cancer. Patients who underwent total mastectomy or breast-conserving surgery plus radiation and received NCCN-recommended systemic therapy were categorized as guideline-concordant.
The multigene signature results or 21-gene recurrence score was used to determine whether chemotherapy was required for patients with HR1, node-negative, early-stage breast cancer. 11, 17, 18 Patients with early-stage HR1/HER2-breast cancer with tumor size .0.5 cm and negative lymph nodes were required to have chemotherapy if the recurrence score was $31 or there was a high risk of recurrence. In addition to routinely collected recurrence scores for breast cancer cases, LTR linked its breast cancer cases with the Oncotype DX (Genomic Health) database to obtain the recurrence risk score that was not captured in the routine data collection. In patients with node-negative, HR1/HER2-disease and tumor size .0.5 cm for whom the recurrence score assay was not performed, the NCCN Guidelines recommend chemotherapy be considered. 11 For patients aged .70 years with a subtype and tumor condition in whom adjuvant chemotherapy was an option, the guidelines suggest that chemotherapy be individualized based on the patient's comorbid conditions. 11 Hence, we used Deyo's enhanced Charlson comorbidity score (CCS) 19 to determine whether chemotherapy should be recommended for these patients. If the patients had any type of Charlson comorbidity, we assumed that adjuvant chemotherapy was not recommended.
Survival
This study assessed overall and breast cancer-specific survival. Eligible patients were followed up to December 31, 2017, if alive. Survival duration was the time between date of initial diagnosis until date of death, date of last contact, or closing follow-up if alive. The underlying cause of death for deceased patients was obtained from the state or the national death file. The event for overall survival was death from any cause. The definition of cause-specific survival for cases with tumor sequences 00 and 01 was based on the SEER cause-specific death classification using ICD-10, 20 whereas for sequence 02 cases, only patients with breast cancer as a cause of death were selected. Patients who died of other causes were censored. Charlson comorbidity, CCS 1, CCS $2). Deyo's enhanced CCS was calculated based on comorbid conditions coded in medical records using ICD-9-CM diagnosis codes. Coding instructions and valid ICD-9-CM diagnosis codes for preexisting comorbidity were based on the Facility Oncology Registry Data Standards (FORDS) manual. 21 The category "comorbidity not documented" included patients without a comorbid condition found in medical records or with an ICD-9-CM diagnosis code not included in the FORDS list.
Statistical Analysis
Descriptive statistics on breast cancer subtype, patient sociodemographic factors, and tumor characteristics by receipt of guideline-concordant AST were assembled, and the Pearson's chi-square test was used to assess the association. We used logistic regression to examine the association between cancer subtype and receipt of guideline-concordant AST for both unadjusted and adjusted models. The Kaplan-Meier method was used to estimate survival time by breast cancer subtype and AST receipt status, and statistically significant difference was based on the log-rank test. Although the Cox proportional hazards regression model, which estimates relative change, is the most popular model to estimate the hazard of an event occurring, it is a challenge to meet the proportional hazard assumption for a model that involves many covariates and assesses 2 different survival outcomes. Instead, we used the semiparametric additive hazard regression (SAHR) model 22, 23 to estimate the regression parameter; this model can estimate the absolute change in risk rather than the relative change. Cox-Snell residuals were used to evaluate the overall fit of the SAHR model. If the model fits the data well, then the Cox-Snell residuals should follow a unit exponential distribution. 24, 25 All analyses were performed using SAS 9.4 (SAS Institute Inc.), and statistical tests of significance were based on a 2-sided test with significance levels of 0.05.
Results
A total of 2,214 eligible female patients with breast cancer were included in the study: 1,582 (71.5%) were white and 632 (28.5%) were black, and 496 (22.4%) of them had either tumor sequence number 01 (192 cases) or 02 (304 cases) ( Table 2 ). Most patients were HR1/HER2-(70.8%), followed by HR-/HER2-(14.4%), HR1/HER21 (10.0%), and HR-/HER21 (4.8%). The mean age was 60.0 years for HR1/HER21, 61.9 years for HR1/HER2-, 56.6 years for HR-/HER21, and 57.1 years for HR-/HER2-. Of 1,568 patients with HR1/HER2-, 35.6% had a recurrence score available and 3.4% were at high risk of recurrence.
Guideline-Concordant AST
An average of 78.6% of the study cohort received guidelineconcordant AST. Women with the HR1/HER21 subtype had the lowest percentage of receipt of adjuvant chemotherapy, hormone treatment, and trastuzumab ( Figure 2 ) among the subtypes and .50% of patients with the HR1/ HER2-subtype either were considered for chemotherapy or did not require chemotherapy. Compared with patients with the HR1/HER21 subtype, patients with other subtypes were more likely to receive guideline-concordant AST with an adjusted odds ratio (aOR) of 4.08 (95% CI, 2.94-5.67) for HR1/HER2-, 3.68 (95% CI, 2.06-6.57) for HR-/HER21, and 3.46 (95% CI, 2.29-5.23) for HR-/HER2-after controlling for other factors (Table 2) . Among patients' sociodemographic factors, only age at diagnosis and poverty level were significantly associated with receipt of guideline-concordant AST (Table 2) . Compared with patients aged ,50 years, those aged 70-79 and $80 years had a 49% (aOR, 0.51; 95% CI, 0.34-0.75) and 78% (aOR, 0.22; 95% CI, 0.14-0.35) lower likelihood of receiving AST after adjusting for other covariants. Patients residing in a census tract $20% below poverty were more likely to be guideline-concordant (aOR, 1.47; 95% CI, 1.09-1.98) than those residing in a census tract ,10% below poverty.
The percentage of patients receiving AST decreased in more advanced stages of disease. Women with stage IIA disease (T0N1M0/T1N1M0/T2N0M0) had a lower likelihood of receiving AST than those with stage IA (T1N0M0), with aOR 0.51 (95% CI, 0.38-0.67), whereas in women with stage IIIB disease (tumor directly extends to chest wall and/or skin), the aOR decreased to 0.11 (95% CI, 0.05-0.22). We also observed that women with a CCS of 1 were more likely to receive AST than those without a CCS (aOR, 1.82; 95% CI, 1.28-2.58), whereas other comorbid groups showed no statistically significant difference.
Survival Outcomes
Median follow-up was 74.8 months (range, 1.1-84.0 months). During the study period, 380 any-cause and 198 cause-specific deaths occurred. Overall, the SAHR models fitted the data well, with the Cox-Snell residuals following a unit-exponential distribution. In the unadjusted model, only women with the HR-/ HER2-cancer subtype had an increased hazard of dying (Table 3) , which implies that on average an additional 27 per 1,000 women with the HR-/HER2-subtype died of any-cause death per year compared with those with the HR1/HER21 subtype. However, for cause-specific survival, women with the HR-/HER21 or the HR-/HER2-subtype had an increased hazard of dying of 0.0199 (P5.0113) and 0.0283 (P,.0001), respectively, compared with those with the HR1/HER21 subtype. After adjusting for guideline-concordant AST and other factors, women with the HR-/HER21 or the HR-/HER2-subtype had a significantly increased hazard of dying of any cause (0.0216 and 0.0266, respectively) or causespecific death (0.0196 and 0.0262, respectively) compared with those with the HR1/HER21 subtype.
The survival probability for women who were guideline-discordant translated to a significantly increased hazard of dying of any cause and cause-specific death compared with those adhering to guidelines in both the unadjusted and the adjusted models (Table 3) . However, the impact of treatment effect on survival reduced after adjustment with a hazard of 0.0322 to 0.0191 for overall survival and 0.0182 to 0.0126 for cause-specific survival. Other covariates, such as patients with Medicaid as the primary insurance, .1 tumor, and advanced cancer stage, showed an increased hazard of death for both overall and cause-specific survival outcomes, and an older age group, a high Bloom-Richardson grade, and Charlson comorbidity were associated with risk of dying of any cause only when compared with their counterparts after adjustment.
When comparing survival among cancer subtypes stratified by guideline-concordant AST status (Figure 3) , we found that among women who received recommended AST, those with the HR-/HER2-subtype had the worst survival in both survival outcomes ( Figure 3A, C ). Yet among guideline-discordant women, those with the HR-/HER2-subtype had worse survival than those with other subtypes observed before year 5 after cancer diagnosis for both any-cause and cause-specific death, whereas at the fifth year after cancer diagnosis, women with the HR-/HER21 subtype had the worst survival ( Figure 3B, D) . Furthermore, we compared survival between patients who were guideline-concordant and guideline-discordant receiving AST stratified by cancer subtype (Figure 4) . Overall, for both survival outcomes, those receiving AST had significantly better survival across all subtypes except cause-specific survival for patients with the HR1/HER21 subtype, which was not a significant difference (P5.2350; Figure 4E ).
Discussion
Clinical decisions for AST for patients with breast cancer profoundly depend on their ER/PR and HER2 status. Although population-based cancer registries have been collecting ER and PR biomarkers from pathology reports and medical charts for .2 decades, it was not until the implementation of the second version of the Collaborative Stage Data Collection System, version 2, 26 on January 1, 2010, that the collection of HER2 test results was required. This is the first population-based study comprehensively evaluating the administration of complete NCCN-recommended AST by breast cancer subtype. In this study, breast cancer subtype was significantly associated with receiving guideline-concordant AST. Women with the HR1/HER21 subtype had the lowest adherence rate (56%) for recommended AST, which may be attributed to all 3 regimens of systemic therapy (hormone, chemotherapy, trastuzumab) being recommended for early-stage disease (stage I, II, and IIIA with N1), except for stage I disease with tumor size #1 cm or favorable histologies (tubular and colloid). Compliance rates for other subtypes were similar, at approximately 80%.
Among sociodemographic variables, age was inversely associated with receipt of AST and remained highly significant after adjusting for cancer subtype and other variables, consistent with previous studies. 12, 13, 27 We observed no differences in guideline concordance for women aged ,70 years, whereas adherence to AST decreased significantly for those aged $70 years. In addition, women living in a census tract $20% below poverty had a higher adherence rate for AST, which could be attributed to Louisiana's unique public hospital system that provides free standard care to patients who are underserved. Regarding the association between receipt of AST and clinical variables, our results indicate that the likelihood of guideline concordance decreases with advanced disease stages and that women with mild comorbidity (CCS 1) are more likely to be guideline-concordant than those without comorbidity, which contradicts findings of other studies. 12 One possible explanation is that previous studies excluded cases for which adjuvant therapy was "considered," whereas our study categorized "considered" systemic therapy as guidelineconcordant despite whether the treatment was received.
Numerous clinical trials have demonstrated the benefit of specific systemic therapy for HR1 or HER21 breast cancer. By jointly considering all AST, we found that women who were guideline-concordant significantly improved in both survival outcomes across the 4 subtypes. The study revealed that women with HR1 disease regardless of HER2 status had almost identical cause-specific survival among those receiving guidelinerecommended AST. Most studies have found that patients with the HR1/HER2-subtype had the best survival rate among subtypes [28] [29] [30] [31] ; nevertheless, our data showed that women with HR1/HER21 tumors had the best survival outcomes except for cause-specific survival in the guideline-concordant cohort. Another key finding from this study is that among patients with HR-, those with HER21 had better overall and cause-specific survival than those with HER2-when they received NCCN-recommended chemotherapy and trastuzumab. Survival differences in these patients were amplified with longer observation. This result confirmed the effect of trastuzumab after chemotherapy for HER21 tumors, demonstrated in several clinical trials, 8, 9 particularly in HR-cohorts. Although 80% of patients with HR-/HER2-were guideline-concordant, their survival rate was worst among the 4 subtypes in both overall and cause-specific death, primarily because there are no effective biomarkertargeted therapies to prolong patient survival and maintain a high relapse rate, 32, 33 and the only option for treatment in these patients is conventional chemotherapy.
We found that women aged $70 years were less likely to be guideline-concordant and had an increased hazard in overall survival, but not in cause-specific survival, compared with their counterparts. After stratifying by age group, we found that women aged $70 years who were guidelineconcordant had a significantly improved overall survival (P5.0009). Treating elderly patients with breast cancer is a complex process, and several factors such as life expectancy, existing comorbidity, treatment complications, benefit, and quality of life are usually considered in treatment decision-making. However, elderly patients with breast cancer should be informed of the standard adjuvant treatment and available options that would benefit them. 34 This study has several strengths. First, it is a population-based study, using high-quality data from a statewide cancer registry. Second, complete treatment information was collected from all sources, including physicians' offices, for all types of systemic therapy, including the Cancer Chemotherapy National Service Center (NSC) number on systemic therapy drugs and the completion status of chemotherapy. This comprehensive process enabled us to separate trastuzumab (NSC number: 688097), which is specifically recommended for patients with HER21, from chemotherapy drugs due to the classification. Third, the linkage of LTR data with the Oncotype DX database allowed us to capture recurrence risk score from multigene signature tests and supplement this site-specific factor in the registry data. The recurrence risk score is an important determinant in chemotherapy administration for patients with node-negative, HR1/HER2-, early-stage breast cancer per the NCCN Guidelines.
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A few limitations should be noted. First, information was lacking on the rationale behind a physician's decision whether to give AST to patients with disease for which the NCCN Guidelines recommend adjuvant therapy be "considered" with certain systemic therapy. In addition, administering recommended adjuvant chemotherapy to patients aged $70 years may vary by physician based on the approach to this age group when taking into consideration patients' existing comorbid conditions, life expectancy, or preference. Another limitation was using the immunohistochemical-based (and/or FISH-based) surrogate cancer subtype to estimate survival, which may not be comparable to gene-expression profile cancer subtype. However, this study demonstrated that the benefits of adhering to guideline-concordant AST among subtypes are the same as in clinical trials based on gene-expression profiling. Finally, the follow-up time may not have been long enough to capture adequate events for subtypes that had a longer survival time, such as HR1, to ensure estimated statistical tests with sufficient power, 35 particularly in cause-specific survival.
Conclusions
This study showed that in a community setting, women with breast cancer had better survival outcomes if they 
